NCT04145115 2026-03-18
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT04817254 2026-03-18
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT03233152 2025-11-21
GlitIpNi
Universitair Ziekenhuis Brussel
Phase 1/2 Active not recruiting
NCT07134842 2025-08-21
WinGlio-ipi
University College, London
Phase 1 Recruiting
NCT04003649 2025-07-10
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
City of Hope Medical Center
Phase 1 Recruiting
NCT03430791 2023-02-02
Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
Baptist Health South Florida
Phase 2 Terminated
NCT03422094 2021-10-27
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Washington University School of Medicine
Phase 1 Terminated
NCT03707457 2020-07-02
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated